Dernières nouvelles pour Saverone 2014 (NASDAQ:SVREW) Stock

Saverone 2014 Ltd provides driver protection solutions. The company develops and deploys ADAS technologies for transportation safety and driver assistance. The company's product restricts the driver from surfing, communicating, and receiving alerts while driving. The company has developed a system that provides a solution to the problem of distracted driving caused by cell phone use, which endangers the driver, passengers, other drivers on the road and pedestrians. Geographially, it operates in Israel and Europe, out of which it derives maximum revenue from Israel.

Saverone 2014 Ltd

Jefferies analyst Jack Slevin initiates coverage on Adtalem Glb Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATGE#NYSE">ATGE</a>) with a Buy rating and announces Price Target of $135.

News

Price Target

Initiation

Analyst Ratings

Adtalem Global Education Inc. Common Stock

ATGE

Jefferies Initiates Coverage On Adtalem Glb Education with Buy Rating, Announces Price Target of $135

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates Unity Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) with a Buy and maintains $4 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Unity Biotechnology, Maintains $4 Price Target

Compass Point analyst Dominick Gabriele initiates coverage on PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a Sell rating and announces Price Target of $56.

PYPL

Compass Point Initiates Coverage On PayPal Holdings with Sell Rating, Announces Price Target of $56

Keybanc analyst Philip Gibbs upgrades ATI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>) from Sector Weight to Overweight and announces $55 price target.

Upgrades

Keybanc Upgrades ATI to Overweight, Announces $55 Price Target

WIIM

GE Vernova shares are trading higher after the company reported better-than-expected Q1 financial results.

Boston Scientific shares are trading higher after the company reported better-than-expected Q1 financial results and raised its 2025 adjusted EPS guidance.

AT&T shares are trading higher after the company reported better-than-expected Q1 financial results.

Guidance

AT&T Sees 2025 Consolidated Service Revenue Growth In The Low-Single-Digit Range, Sees Adjusted EBITDA Growth Of 3% Or Better

Central Pacific Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPF#NYSE">CPF</a>) reported quarterly earnings of $0.65 per share which beat the analyst consensus estimate of $0.63 by 3.17 percent. This is a 35.42 percent increase over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $57.70 million which beat the analyst consensus estimate of $57.22 million by 0.85 percent. This is a 14.97 percent increase over sales of $50.19 million the same period last year.

Earnings

Earnings Beats

Central Pacific Financial Q1 Adj. EPS $0.65 Beats $0.63 Estimate, Sales $57.70M Beat $57.22M Estimate

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) is looking for Q2 Adj EPS of $0.71-$0.73 vs $0.71 analyst estimate..

Boston Scientific Sees Q2 Adj EPS $0.71-$0.73 vs $0.71 Est and estimates net sales growth for the second quarter of 2025 to be in a range of approximately 17.5 to 19.5 percent on a reported basis versus the prior year period

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) is looking for Q2 GAAP EPS of $0.45-$0.47 vs $0.48 analyst estimate..

Boston Scientific Sees Q2 GAAP EPS $0.45-$0.47 vs $0.48 Est

Telsey Advisory Group analyst Joseph Feldman maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Outperform and lowers the price target from $275 to $235.

AMZN

Telsey Advisory Group Maintains Outperform on Amazon.com, Lowers Price Target to $235

Walgreens Has Teamed Up With Guild To Launch PharmStart, A First-of-its-kind, Fully Funded Online Education Program Designed To Help Eligible Team Members Meet The Prerequisite Requirements For Pharmacy School

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) raises FY2025 Adj EPS guidance from $2.80-$2.87 to $2.87-$2.94 vs $2.86 analyst estimate..

Boston Scientific Raises FY2025 Adj EPS Guidance from $2.80-$2.87 to $2.87-$2.94 vs $2.86 Est and estimate net sales growth for the full year 2025 to be approximately 15 to 17 percent versus the prior year period

Travel+Leisure (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNL#NYSE">TNL</a>) .

Travel+Leisure expects FY 2025 Adjusted EBITDA of $955 million to $985 million

AT&T Sees FY2025 Adj EPS Guidance of $1.97-$2.07 vs $2.04 Est

Travel+Leisure expects Q2 2025 Adjusted EBITDA of $245 million to $255 million

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) affirms FY2025 GAAP EPS guidance from $1.86-$1.93 to $1.86-$1.93 vs $1.96 analyst estimate..

Boston Scientific Affirms FY2025 GAAP EPS Guidance of $1.86-$1.93 vs $1.96 Est

AT&T Q1 Adj. EPS $0.51 Beats $0.49 Estimate, Sales $30.63B Beat $30.35B Estimate

Prosperity Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PB#NYSE">PB</a>) reported quarterly earnings of $1.37 per share which beat the analyst consensus estimate of $1.36 by 0.74 percent. This is a 16.1 percent increase over earnings of $1.18 per share from the same period last year. The company reported quarterly sales of $306.68 million which missed the analyst consensus estimate of $308.17 million by 0.48 percent. This is a 10.67 percent increase over sales of $277.11 million the same period last year.

Comments

Saverone 2014

Actualités

Dernières nouvelles pour Saverone 2014 (NASDAQ:SVREW) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL